Cover Image
市場調查報告書

寡樹突膠質瘤:開發中產品分析

Oligodendroglioma - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213100
出版日期 內容資訊 英文 148 Pages
訂單完成後即時交付
價格
Back to Top
寡樹突膠質瘤:開發中產品分析 Oligodendroglioma - Pipeline Review, H2 2017
出版日期: 2017年09月30日 內容資訊: 英文 148 Pages
簡介

寡樹突膠質瘤,是神經膠質瘤之一,含礦品質沉著物(鈣化),有出血範圍,偕同囊胞。症狀是,發作、頭痛、人格的變化等。

本報告提供寡樹突膠質瘤的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的新聞和發表開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等。

簡介

  • 調查範圍

寡樹突膠質瘤 概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的開發平台
  • 各大學/機關的開發平台
  • 企業開發中的產品
  • 大學/機關研究中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • AngioChem Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cavion LLC
  • Celldex Therapeutics Inc
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Immatics Biotechnologies GmbH
  • Ipsen SA
  • Leadiant Biosciences Inc
  • Millennium Pharmaceuticals Inc
  • Northwest Biotherapeutics Inc
  • Novartis AG
  • Pfizer Inc
  • Tocagen Inc

藥物簡介

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9744IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H2 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.

Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 6 and 11 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Oligodendroglioma - Overview
    • Oligodendroglioma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Oligodendroglioma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Oligodendroglioma - Companies Involved in Therapeutics Development
    • AngioChem Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Co
    • Cavion LLC
    • Celldex Therapeutics Inc
    • Eli Lilly and Co
    • F. Hoffmann-La Roche Ltd
    • Immatics Biotechnologies GmbH
    • Ipsen SA
    • Leadiant Biosciences Inc
    • Millennium Pharmaceuticals Inc
    • Northwest Biotherapeutics Inc
    • Novartis AG
    • Pfizer Inc
    • Tocagen Inc
  • Oligodendroglioma - Drug Profiles
    • abemaciclib - Drug Profile
    • afatinib dimaleate - Drug Profile
    • alisertib - Drug Profile
    • bevacizumab - Drug Profile
    • CDX-1401 - Drug Profile
    • Cellular Immunotherapy for Gliomas - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • dasatinib - Drug Profile
    • DCVax-L - Drug Profile
    • flucytosine + TBio-01 - Drug Profile
    • flucytosine ER + vocimagene amiretrorepvec - Drug Profile
    • IMA-950 - Drug Profile
    • irinotecan hydrochloride - Drug Profile
    • irinotecan hydrochloride + TBio-02 - Drug Profile
    • mibefradil dihydrochloride - Drug Profile
    • nilotinib - Drug Profile
    • p28 - Drug Profile
    • paclitaxel trevatide - Drug Profile
    • palbociclib - Drug Profile
    • procarbazine hydrochloride - Drug Profile
    • TBX.OncV NSC - Drug Profile
  • Oligodendroglioma - Dormant Projects
  • Oligodendroglioma - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Oligodendroglioma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Oligodendroglioma - Pipeline by AngioChem Inc, H2 2017
  • Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Oligodendroglioma - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Oligodendroglioma - Pipeline by Cavion LLC, H2 2017
  • Oligodendroglioma - Pipeline by Celldex Therapeutics Inc, H2 2017
  • Oligodendroglioma - Pipeline by Eli Lilly and Co, H2 2017
  • Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Oligodendroglioma - Pipeline by Immatics Biotechnologies GmbH, H2 2017
  • Oligodendroglioma - Pipeline by Ipsen SA, H2 2017
  • Oligodendroglioma - Pipeline by Leadiant Biosciences Inc, H2 2017
  • Oligodendroglioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Oligodendroglioma - Pipeline by Northwest Biotherapeutics Inc, H2 2017
  • Oligodendroglioma - Pipeline by Novartis AG, H2 2017
  • Oligodendroglioma - Pipeline by Pfizer Inc, H2 2017
  • Oligodendroglioma - Pipeline by Tocagen Inc, H2 2017
  • Oligodendroglioma - Dormant Projects, H2 2017
  • Oligodendroglioma - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Oligodendroglioma, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top